📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. (2018)

First Author: Woodcock VK

Attributed to: Centre for Integrated research into Musculoskeletal Ageing (CIMA) Renewal funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2017.484

PubMed Identifier: 29438361

Publication URI: http://europepmc.org/abstract/MED/29438361

Type: Journal Article/Review

Volume: 118

Parent Publication: British journal of cancer

Issue: 6

ISSN: 0007-0920